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Abst rac t
Introduction: The patients clinically diagnosed with psoriasis were investigated for drug use that may trigger 
psoriasis. 
Aim: To minimize the triggering drug use and help the medical treatment of psoriasis patients.
Material and methods: The study involved 289 psoriatic patients who attended our clinic in 2010–2012 and were 
asked to bring their drug lists of the last year, which they obtained from the pharmacy’s record system. They were 
advised not to use the drugs that may trigger psoriasis. Data analyses were performed using SPSS program version 
19.0. 
Results: A total of 289 patients were included in the study. Two hundred and twenty-one patients were using 
non-steroidal anti-inflammatory drugs; 133 patients were using anti-reflux drugs; 35 patients were using antidia-
betic drugs; 31 patients were using calcium-channel blockers and 24 patients were using b-blockers. In our study 
group, there was no significantly difference between median PASI scores of the patients using a triggering drug 
and those of who are not using a triggering drug. However, there was a positive low correlation between PASI rates 
and numbers of drugs used (r = 0.180, p = 0.013).
Conclusions: Many other factors may trigger psoriasis, therefore the effect of stopping or minimizing the drug 
use on disease remission is not known. Because of the high triggering drug use rate, it is important to enlighten 
psoriasis patients about triggering drugs.
Key words: psoriasis, triggering drugs, b-blockers, non-steroidal anti-inflammatory drugs.
Introduction
Adverse drug reactions and medication errors are 
major public health problems. Therefore, taking a care-
ful medical history, superintend redundant medicine 
consumption and drug interaction are a critical step for 
prevention. There are many reports in the literature re-
garding the initiating, triggering and aggravated roles of 
drugs in psoriasis etiopathogenesis [1–8]. However, it is 
difficult to prove in an antidepressant receiving patient 
whether the stress or drug is a triggering factor. It is the 
same in the antibiotic use; it is unclear whether the 
infection or the used antibiotic is the triggering factor. 
However, effects of some drugs are more prominent. Trig-
gering effects of drugs are indicative in some drugs, like 
non-steroidal anti-inflammatory drugs (NSAIDs) and/or 
b-blockers, because lesions are recovered after the drug 
discontinuation. The most commonly reported drugs, 
which trigger psoriasis in the literature, are NSAIDs, 
b-blockers, synthetic antimalarial agents, lithium and 
tetracycline [2, 4–6].
Even biological agents, which have been reported as 
successful in psoriasis treatment in recent years, have 
also been reported that they may cause exacerbations 
of psoriasis lesions [8–11].
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Although there are no definite data related to psori-
asis incidence, general consensus of dermatologists has 
been that the number of psoriasis cases has increased 
in the recent years. Socioeconomic conditions and un-
controlled drug use, which is a new trend, and also easy 
contamination of diseases in crowded environments are 
believed to be triggering factors in the psoriasis increase. 
It has been accepted that drugs act like exogenous anti-
gens and they sometimes play triggering roles in psoria-
sis pathogenesis [2, 3, 6].
Aim
The goal of this study was to investigate a correlation 
between triggering drugs used in patients with psoriasis 
and mean PSI scores, and to draw attention to the trig-
gering drug use in those patients.
Material and methods
Patients, who came to our outpatient clinic between 
2010 and 2012 and were diagnosed with psoriasis, were 
requested to bring their drug lists, which were record-
ed in the pharmacy’s computer system. After reviewing 
those lists, we have informed patients about the drugs 
that may have possibly caused the triggering. We exclud-
ed patients, who were not recorded in the Social Security 
System (SGK), and whose drug lists were only provided 
from anamnesis information, from the study. A total of 
289 cases were included in the study. By using the phar-
macy lists, drugs, which were used at least for 3 months 
and at most for 32 months were reviewed. Time intervals 
in the lists were related to disease durations.
Statistical analysis
Statistical analysis of data was performed using 19.0 
version of the SPSS package program. Normal distribu-
tion of data was evaluated by Kolmogorov-Smirnov test. 
The level of significance was accepted as p < 0.05. De-
scriptive statistics were presented as mean ± standard 
deviation or median (min-max) values for continuous 
variables. In addition, frequency (n) and percentage 
(%) values were used for categorical variables. It was 
evaluated whether there was any difference in medi-
an of PASI scores between triggering drug users and 
non-users in independent groups using non-parametric 
test (Mann-Whitney U test) analysis. It was evaluated 
whether there was any correlation between PASI rates 
and numbers of drugs used using Spearman’s correlation 
coefficient.
Results
Median age of cases was 45.00 (min: 8, max: 86) 
years; median age for females was 43.00 (min: 8, max: 
84) years and median age for males was 47.00 (min: 8, 
max: 86) years. In this present study, 156 females 
(53.98%) and 133 males (46.02%) were included. Disease 
duration was 12.51 ±15.52; Psoriasis Area Severity Index 
(PASI) value was 5.50 ±0.45 (min: 0,  max: 42) points. Of 
289 cases, 221 were using NSAIDs (76.5%), and drug dis-
tribution of patients was as follows: 68 patients (30.8%) 
diclofenac, 70 patients (31.7%) ketoprofen, 37 patients 
(16.7%) ibuprofen, 61 patients (27.6%) naproxen, 35 pa-
tients (15.8%) acetyl salicylic acid, 68 patients (30.3%) 
flurbiprofen, 1 patient (0.5%) acemetacin, and 21 patients 
(9.5%) indomethacin. The list of patients, who used 
those drugs concomitantly, is given in Table 1. 
The number of cases using b-blocker drugs was 24 
(8.3%), and the number of ACE inhibitor recipients was 
59 (20.4%). Of 31 patients using calcium channel blockers 
(CCB), 2 (6.5%) were receiving diltiazem, and 9 (29.0%) 
were receiving nifedipine. The number of antidepressant 
recipients was 105 (37%); numbers of citalopram, flu-
oxetine, and trazodone recipients were 50, 9, and 5, re-
spectively. There was no patient receiving lithium. Num-
bers of patients receiving drugs for diabetes and gastric 
Table 1.Triggering drugs reported by patients with psoriasis
Drug Number of triggering drugs (n)
Diclofenac Ketoprofen Ibuprofen Naproxen Acetyl 
salicylic acid
Flurbiprofen Acemetacin Indomethacin
Diclofenac 68 28 10 15 12 21 0 5
Ketoprofen 28 70 13 20 10 21 1 8
Ibuprofen 10 13 37 11 4 5 0 3
Naproxen 15 20 11 61 9 21 1 8
Acetyl salicylic 
acid
12 10 4 9 35 11 0 2
Flurbiprofen 21 21 5 21 11 68 1 5
Acemetacin 0 1 0 1 0 1 1 0
Indomethacin 5 8 3 8 2 5 0 22
Postępy Dermatologii i Alergologii 5, October / 2014296
Zerrin Ogretmen, Ulku Askin, Meliha Merve Hiz, Sibel Cevizci
diseases were 31 (10.7%), and 113 (39%) respectively. 
Seventeen (6%) patients were taking terbinafine, and 
40 (14%) were taking corticosteroids. None of patients 
was receiving antimalarial drugs, whereas 16 (5.6%) pa-
tients were receiving sulphonamide; 10 (3.5%) were on 
salazopyrin and 7 (2.4%) were on trimethoprim sulfame-
thoxazole. Of patients, 111 (38.4%) were taking penicillin, 
and 8 (2.8%) were taking tetracycline. The number of 
antidiabetic users was 31 (10.7%). Concomitant use of 
NSAIDs with b-blocker agents was detected in 22 cases 
(7.6%), and concomitant use of NSAIDs with antidiabetic 
agents was observed in 27 cases (9.3%). Concomitant in-
take of NSAIDs with antibiotics was observed in 91 cases 
(31.5%), whereas NSAIDs-gastric agent combination was 
observed in 118 cases (40.8%).
NSAID-antibiotic-b-blocker combination was ob-
served in 12 cases (4.2%); NSAID-antibiotic-antidiabetic 
agent combination was observed in 5 cases (1.7%); and 
NSAID-antibiotic-b-blocker-antidiabetic combination 
was used in 2 cases (0.7%). Mean disease duration of 
patients was 12.5 ±15.5 years.
Median value of PASI score was 5.55 ±0.45 points in 
the total patient group. In patients, who received none of 
triggering drugs, the median value of PASI score was 6.15 
(min: 2, max: 22) points. Median PASI score of patients, 
who took more than one drug was 5.50 (min: 0, max: 
42) points (p = 0.835). There was a positive low correla-
tion between PASI rates and numbers of drugs used (r = 
0.180, p = 0.013).
Discussion
In our study, we investigated the rate of triggering 
drugs used by patients with psoriasis. The most com-
monly used drugs were NSAIDs, antibiotics and anti-
depressants, and gastric medications (cimetidine, fa-
motidine, ranitidine) were following them. Antidiabetic 
agents, b-blockers, CCBs and ACE inhibitors, which have 
been increasingly used for type II diabetes and hyperten-
sion that are metabolic syndrome components related 
to obesity in the recent years, have also made up a sig-
nificant problem in psoriasis. Because medications for 
hypertension and diabetes should be used permanently, 
their selection has become much more important. In line 
with the literature, although we observed that as the rate 
of triggering drug use was increased, the PASI rate was 
also increased in our study. 
There are many studies, which have indicated that 
NSAIDs trigger psoriasis [1–8, 12, 13]. It was defined 
that ketoprofen (70 cases, 24.2%), diclofenac (68 cas-
es, 23.5%), flurbiprofen (68 cases, 23.5%) and naproxen 
(61 cases, 21.1%) were the most commonly used NSAIDs; 
and they were followed by ibuprofen (37 cases, 12.8%), 
acetyl salicylic acid (35 cases) and indomethacin (22 cas-
es) in our study. Moreover, there were many patients, who 
were taking one or more of those drugs together. Median 
value of PASI score was 5.55 ±0.45 points in the total pa-
tient group. In patients, who received none of triggering 
drugs, the median value of PASI score was 6.15 (min: 2, 
max: 22) points. Median PASI score of patients, who took 
more than one drug was 5.50 (min: 0, max: 42) points. 
There was no statistically significant difference in median 
PASI scores between triggering drug users and non-users.
b-Blockers have been frequently reported as trigger-
ing drugs for psoriasis in the literature [14–18]. b-Blocker 
use was observed in 26 of our patients. ACE inhibitors 
have also been reported as triggering drugs for psoriasis 
[19–22]. Our 63 patients (22%) were receiving ACE inhibi-
tors. In our study group, 14 patients (4.9%) were receiving 
the ACE inhibitor-b-blocker combination.
It was reported in previous studies that also calcium 
channel blockers triggered psoriasis [23–26]. In our study, 
31 patients (11%) were taking calcium channel blockers. 
Seven of our patients (2.4%) were taking CCB-ACE inhib-
itor combination, whereas 7 patients (2.4%) were taking 
CCB-b-blocker combination.
Stress factor is important as an initiator and booster 
for lesions. Antipsychotic drug use has been increasing 
recently because of stress [27–33]. In the literature, it has 
been indicated that activation of psoriasis lesions has 
been caused especially by lithium use [27–29]. In our 
study, there was no lithium receiving patient, but anti-
depressant distribution among the cases was as follows: 
citalopram = 50 (17.3%), fluoxetine = 9 (3.1%) and trazo-
done = 5 (1.7%).
Also antibiotics are one of uncontrollably used drug 
groups. There are publications about their triggering roles 
of psoriasis. Especially commonly used penicillin [34], tet-
racycline [35] and sulfonamides [36] have been reported 
as triggers. In our study, 111 patients (38.4%) were using 
penicillin, whereas 8 patients (2.8%) were taking tetra-
cycline. Among sulfonamide using 16 patients (5.6%), 
9 were taking salazopyrin and 7 were taking trimetho-
prim sulfamethoxazole. However, because those drugs 
were used for a short time and infections were triggers for 
psoriasis, drugs which were used for infection treatments 
were not mentioned as frequently as analgesics, antihy-
pertensive and antidiabetic agents in the literature [1–8].
In the literature, it was reported that antidiabetic 
drugs could also trigger psoriasis [37–40]. In our study, 
the number of patients on antidiabetic agents was 
35 (12%), and other drugs, which our patients used and 
were known as triggers, were terbinafine [41–43] and an-
timalarial drugs [1–8]. Terbinafine was used by 17 cases 
(6%). There was no patient on the antimalarial agents. 
There are contradictory publications in the literature 
about gastric medications. Although there have been 
publications, which indicated that they could cause pso-
riasis-like skin rash [44], there were also publications, 
which indicated that they were not triggers, even they 
could be used in the treatment [45–48]. In our study, 
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the number of patients on gastric medications was 113 
(39%).
It has also been reported that alcohol and its metab-
olites might be triggering skin lesions of psoriasis [49, 
50]. Moreover, as alcohol use increases liver toxicities of 
systemic antipsoriasis drugs, patients should be warned 
about alcohol use. In our study, we asked about alcohol 
drinking habits of patients, and informed them about its 
triggering effect. In our study, 86 cases (31%) were taking 
alcohol. Two of our cases were hospitalized and received 
treatment for drinking alcohol, and it was observed that 
numbers of their lesions were decreased.
As concomitance of psoriasis with metabolic syndrome 
is a known fact, patients should also be warned about 
obesity. Health problems, which appear along with obesi-
ty, and drugs used for those conditions (antihypertensives, 
antidiabetics) complicate struggling against the disease. 
The aim of this present study was not to define which 
drugs triggered the disease, but to direct attention of 
patients with psoriasis to possible triggers. Moreover, 
healthcare personnel also have important responsibili-
ties. Existence of psoriasis should be definitely reviewed 
and investigated before recommending or prescribing es-
pecially a triggering drug. In the literature it was reported 
that roles of triggering drugs could be encountered not 
only after the first use but months after the use, so that 
drug effect could be missed [8, 9, 23–25, 30]. Even af-
ter treatment with biological agents, drug effects, which 
might increase lesions, might be observed months after 
the use [8, 9]. Increased PASI score in patients with many 
drugs use has indicated roles of drugs. Multiple drug use 
and high PASI scores of advanced age patients (over 
50 years) may be an indicator.
In our study group, there was no significantly differ-
ence between median PASI scores of the patients using 
a triggering drug and those of whom are not using a trig-
gering drug. This result in our study may be caused by 
taking into consideration only drugs reported as trigger-
ing in the literature not the others. Some drugs which 
are used by our patients and not reported as triggering 
before in the literature may have been triggering. In 
addition, it is known that there have been several trig-
gering factors such as alcohol consumption, smoking, 
infections, stress other than drugs in the patients with 
psoriasis. Therefore, in order to determine triggering 
roles of the drugs, during statistical analysis, PASI scores 
of the patients who have no triggering factor should be 
compared. On the other hand, it seems that it is not pos-
sible to find enough cases in practice. However, we found 
that there was a positive low correlation between PASI 
rates and numbers of drugs used (r = 0.180, p = 0.013).
Conclusions
Treating psoriasis patients, who are receiving psoriasis 
triggering drugs (77% NSAIDs, 8.3% b-blocker, 37% anti- 
depressants), is similarly difficult as treating a subject 
with the strawberry allergy using only antihistaminics.
According to pharmacogenetic studies, the same 
drug may not show the same effect in all subjects, but 
careful use of drugs and increasing awareness of pa-
tients against the disease are important. Thus, we be-
lieve that we can be more helpful to our patients. If we 
emphasize that the drugs they are using can also trigger 
their diseases and we provide that they are more careful 
about the issue, then we may also reveal drugs, which 
are not on the list yet. Physicians working at the primary 
healthcare settings should be warned about this issue. 
We believe that especially a warning in the patient leaflet 
sheet, which underlines that b-blockers should be care-
fully used in subjects with psoriasis, is not being read by 
patients. 
Currently, we observe that many psoriasis patients 
accept their diseases with some localized plaques on 
their bodies, and they continue living by using topical 
preparations from time to time. We can inform our pa-
tients about triggering factors in a very limited time at 
the outpatient clinic visits with the help of a newsletter 
or a copy of the text about drugs prepared by the derma-
tology association. Sunny climate and thermal springs 
of our country as well as easily and cheaply reached sea-
food facilities provide conditions helpful for psoriasis 
treatment. We can be more helpful to our patients by 
using protective, rehabilitating and life quality increasing 
methods like group therapies instead of antidepressants, 
struggling against obesity, and using drugs from other 
groups rather than psoriasis triggering ones. We believe 
that another important topic is that healthcare trainings 
should be given to parents with psoriasis how to protect 
their children (with genetic susceptibility background) 
from triggering drugs.
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